Back to top

Image: Bigstock

ImmunoGen, Inc.

Read MoreHide Full Article

ImmunoGen has made a significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine (platinum-resistant ovarian cancer). Successful development and subsequent approval will be a huge boost for the company as ovarian cancer market represents a huge potential. The company’s collaborations with big healthcare companies not only validate its technology but also provides it with funds in the form of milestone and royalty payments. The company’s shares have outperformed the broader industry so far this year. However, ImmunoGen is heavily dependent on its lead candidate, mirvetuximab soravtansine. Hence, any kind of development or regulatory setback could hamper the stock. Most other pipeline candidates are still a long way from entering the market, which also raises concern.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


ImmunoGen, Inc. (IMGN) - free report >>

Published in